Permira Emerging as Strong Contender in Triton-Backed Pharmanovia Auction
Permira, a global private equity firm, is emerging as a strong contender in the auction for Pharmanovia, a speciality pharmaceutical company backed by Triton Partners.
The auction is expected to close in the coming weeks, and Permira is one of several bidders that have submitted offers. Other potential bidders include CVC Capital Partners, Carlyle Group, and KKR & Co.
Pharmanovia is a leading provider of speciality pharmaceuticals in Europe. The company has a strong portfolio of products, including treatments for rare diseases and cancer. Pharmanovia also has a growing pipeline of new products in development.
Triton Partners acquired Pharmanovia in 2017 for €1.2 billion. The company has since grown significantly, with revenue increasing by 50% over the past five years.
Permira is a well-known investor in the healthcare sector. The firm has a strong track record of investing in and growing speciality pharmaceutical companies. Permira is also a major investor in the UK, and the acquisition of Pharmanovia would be a significant investment in the UK healthcare sector.
The auction for Pharmanovia is expected to be competitive. However, Permira is well-positioned to win the auction. The firm has a strong track record in the healthcare sector, and it is a major investor in the UK. Permira is also willing to pay a premium for Pharmanovia, which could give it an edge over other bidders.
Key Takeaways
- Permira is emerging as a strong contender in the auction for Pharmanovia.
- Other potential bidders include CVC Capital Partners, Carlyle Group, and KKR & Co.
- Pharmanovia is a leading provider of speciality pharmaceuticals in Europe.
- Triton Partners acquired Pharmanovia in 2017 for €1.2 billion.
- Permira is a well-known investor in the healthcare sector.
- The auction for Pharmanovia is expected to be competitive.
